Want  to  lunch one-on-one with a senior exec from a major pharma company and help people in the developing world at the same time?

UK/US Life science consulting firm Alacrita,  based in the Cambridge Innovation Center, has launched a benefit auction in which you can bid for a two-hour, one-to-one lunch with senior executives from the pharmaceutical industry who have donated their time to the appeal.

According to Alacrita Partner Rob Johnson,   the appeal aims to raise money for WaterAid, an international non-profit organization that  transforms the lives of people in the world’s poorest countries by improving access to safe water and sanitation.

Bidding opened Monday 3^rd December and closes on Thursday 13^th December on 5pm EST/10pm GMT.

In order to bid,  click on a name, below. You will be redirected to eBay for bidding.

• Heather Bell, Head of Corporate Strategy and Shaun Grady, Head of Business Development at AstraZeneca (one lunch)
• Moncef Slaoui, Chairman, Research & Development at GlaxoSmithKline
• Douglas Giordano, Senior Vice President, Worldwide Business Development at Pfizer
• Susan Silbermann, President and General Manager, Vaccines, Specialty Care Business Unit and Polly Murphy Vice President, Specialty Care Business Unit Business Development at Pfizer (one lunch)
• Graham Brazier, Vice President, Business Development, Strategic Transactions Group at Bristol-Myers Squibb
• Pamela Demain, Executive Director, Corporate Licensing at Merck
• Susan Jane Herbert, Executive Vice President and Head of Global Business Development and Strategy and Annalisa Jenkins, Executive Vice President and Head of Global Drug Development & Medical and Belen Garijo, Executive Vice President and Chief Operating Officer at Merck Serono (one lunch)

Bidding  will be open until 13^th December, 5pm EST/10pm GMT.

Johnson said: “We are thrilled to launch this year’s seasonal appeal to raise funds for WaterAid. 783 million people, or one in ten of the world’s population, live without access to safe water and last year WaterAid reached 1.6 million people with water and 1.9 million people with sanitation in 27 countries. ”

David Winder, CEO of WaterAid, America added: “We are delighted that Alacrita has chosen to  donate the proceeds of their charity auction to  WaterAid.  Every day, 2,000 children die from water-related diseases that could easily be prevented.  The funds raised will help us reach more of the world’s poorest people with safe, clean water and sanitation.  These vital basic services are essential for saving  lives, improving health and reducing poverty in the world’s poorest countries.”

–Anita M. Harris
New Cambridge Observer is a publication of the Harris Communications Group,  an award-winning PR/content marketing and social media firm specializing in health, science, technology and energy.

Four Massachusetts-Israeli business collaborations have received a total of $1.3M in grant funding under the  Massachusetts-Israel Innovation Partnership (MIIP)–a  formal collaboration between the State of Israel and the Commonwealth of Massachusetts to encourage and support innovation and entrepreneurship between Massachusetts’ and Israel’s life sciences, clean energy and technology sectors.

The grants were announced yesterday at the  2012 BIO International Convention in Boston by Massachusetts  Governor Deval Patrick and  Israeli Chief Scientist Avi Hasson, of  MATIMOP, the  Israel Ministry of Industry, Trade and Labor.

The four winning projects are:

• SBH Sciences (Natick) and Improdia (Israel) will work together toward the development and manufacture of a chronic inflammation-dependent immunosuppression prognostic kit. SBH will receive $184,000 from the Center and Improdia will receive $202,000 from Israel’s OCS.SBH Sciences is a discovery and preclinical contract research organization with expertise in production and analysis of cytokines and biomarkers. Improdia is a life science start-up focused on implementing novel biomarkers for immune system modulating therapies– using  simple blood tests for patients with chronic disease.

•  Automated Medical Instruments (AMI – Needham) and STI Lasers (Israel) will develop new technology involving radio frequency energy to perform circumferential ablation of the pulmonary veins. AMI will receive $116,000 from the Center and STI Lasers will receive $110,000 from OCS. AMI is a start-up medical device company developing novel technology to perform atrial fibrillation treatment. STI Lasers is a medical device company specializing in laser cutting, micromachining and finishing of miniature metal components.“AMI is developing the CircumBlator™,  to offer a reliable and curative, minimally invasive treatment for millions of patients with atrial fibrillation, a disease that causes over 20 percent of strokes and untold misery,” said Martin Sklar, President and CEO of Automated Medical Instruments.

• Lantheus Medical Imaging, Inc. (North Billerica) and Check-Cap (Israel) will  develop a novel 3-D imaging capsule that can be used to screen for polyps and lesions associated with colorectal cancer. Lantheus will receive $300,000 from MTC and Check-Cap has been selected to receive at least an equal amount from OCS. Lantheus  develops, manufactures and distributes innovative diagnostic imaging agents. Check Cap is a medical device company located in Mount Carmel, Israel with a “breakthrough” solution for Colorectal Cancer Screening.  “As a global leader in diagnostic imaging, Lantheus is dedicated to providing physicians with breakthrough new tools to enhance patient care. Teaming up with Check-Cap to develop and manufacture a cutting-edge imaging capsule further advances this ongoing commitment,” said Don Kiepert, President and CEO, Lantheus Medical Imaging.

• FloDesign Sonics (Wilbraham) and Transbiodiesel (Israel)  will use FloDesign’s acoustic molecule separation technology to separate oil that can be used to create fuel from Transbiodiesel’s oil-generating algae. FloDesign Sonics will receive $55,000 from MassCEC and Transbiodiesel will receive $20,958 from OCS. FloDesign Sonics uses a novel ultrasonic acoustophoretic separation technology developed at Western New England University for a more efficient approach to wastewater treatment and micro-algae harvesting for biofuels. Transbiodiesel is a start- up company with a novel technology for producing biodiesel fuels from a variety of oils

The MIIP program was first announced in June 2011 at the BIO International Convention in Washington, D.C. and the first joint solicitation for proposals was launched in September 2011 by MATIMOP on the Israeli side and by the three participating Massachusetts agencies: the Massachusetts Life Sciences Center, the Massachusetts Technology Collaborative (MTC) and the Massachusetts Clean Energy Center (MassCEC). Total funding for the current projects is approximately $3m.

The partnership came as a result of a 2011 trade mission in which  Governor Patrick and a coalition of Massachusetts business executives and senior government officials explored growth opportunities of common interest for Massachusetts’ and Israel’s innovation industries. During that mission Governor Patrick and Shalom Simhon, Israeli Minister of Industry, Trade and Labor, signing on behalf of their respective states, signed a Memorandum of Understanding (MOU) in Jerusalem. MIIP was established to implement the MOU’s framework.

Massachusetts is the first U.S. state to establish a significant industrial R&D program with the State of Israel, according to a press release issued yesterday by Patrick’s office.

Today there are nearly 100 companies with Israeli founders or Israeli-licensed technologies in Massachusetts, according to the release.  In 2009, these companies employed nearly 6,000 people and generated $2.4 billion in direct revenue for the state. Local firms exported over $180 million worth of goods to Israel in 2009. Home to 377 hospitals and 37,000 practicing physicians, Israel is an important market for health-related technologies.

The New England-Israel Business Council, the US-Israel Science and Technology Foundation, the Government of Israel Economic Mission to North America, the Consulate General of Israel to New England and MOITI have all played an important role in promoting the program, according to the release.

–Anita M. Harris

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.

PRESS RELEASE

· New antibody program targets Tau protein, a major cause of Alzheimer’s disease

· License agreement potentially worth more than Swiss Francs 400 Million (approximately USD 418 million*)

Lausanne, Switzerland, 18 June, 2012 – AC Immune SA, today announced that it has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for the research, development and commercialization of AC Immune’s anti-Tau antibodies for the potential treatment of Alzheimer’s disease and other neurodegenerative diseases.

Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments totaling more than Swiss Francs 400 million (approximately USD 418 million*) for Alzheimer´s disease and other indications. Additionally, AC Immune is eligible to receive royalties on net sales of products resulting from the collaboration. Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. Genentech will have global responsibility for pre-clinical and clinical development, manufacturing and commercialization of antibodies resulting from the collaboration.

Prof. Andrea Pfeifer, CEO of AC Immune said: “We are delighted to continue our excellent relationship with Genentech through this second landmark deal to fight Alzheimer’s disease. This underlines Genentech’s trust in AC Immune’s proprietary technology platform and we are confident in our joint abilities to develop not only
first-in-class but also best-in-class medication for one of the biggest healthcare problems of this century.”

“This second licensing deal gives us financial security to continue AC Immune’s
world-leading efforts to develop disease modifying therapies and diagnostics. We are now recognized as having one of the broadest and most advanced Alzheimer’s pipelines in the industry”, remarked Martin Velasco, Chairman of The Board of AC Immune .

Commenting on the deal, James Sabry, Genentech’s Vice President of Partnering , said: “Genentech is committed to bringing innovative treatments to patients suffering from devastating neurodegenerative diseases, and is developing a number of approaches to tackle Alzheimer’s disease. The addition of this anti-Tau program to our CNS pipeline complements other approaches we are investigating, including crenezumab which we in-licensed from AC Immune in 2006.”

About the anti-Tau Program

The Tau protein forms twisted fibers inside brain cells and build tangles that are considered by many in the scientific community as the second major cause of Alzheimer’s disease besides Abeta-plaques. The anti-Tau antibodies were discovered and humanized by AC Immune through its proprietary SupraAntigen TM technology.

“The anti-tau-antibodies have proven highly specific to misfolded Tau in relevant animal models for Alzheimer’s disease and are therefore well suited to be developed as a disease-modifying drug. This has significant potential as there are at present no known cures for Alzheimer’s disease,” said Dr. Andreas Muhs, Chief Scientific Officer
of AC Immune .

About Crenezumab

An anti-Abeta antibody, crenezumab was discovered and humanized by AC Immune. It is designed to bind to amyloid beta (Abeta), the main constituent of amyloid plaque in the brains of patients with Alzheimer’s disease. Abeta is considered to be a major cause in the development of the disease. Genentech is currently evaluating crenezumab in a Phase II clinical study in Alzheimer’s patients with mild to moderate symptoms. At the time the deal with Genentech was announced in December 2006, it was stated to have a potential total value of more than USD 300 million in clinical and regulatory milestone payments to AC Immune, excluding royalties.

In May 2012, crenezumab was selected to be tested in the world’s first-ever prevention trial in healthy individuals who are genetically destined to develop Alzheimer’s disease. This landmark study to investigate whether an anti-amyloid treatment can stave off the disease is being run by the US National Institutes of Health (NIH), the Banner Alzheimer’s Institute (BAI), the University of Antioquia in Colombia and Genentech.

About Alzheimer’s Disease

Alzheimer´s is the most common form of dementia. It is degenerative, irreversible and terminal. The memory and thinki ng of the patients is progressively destroyed. Besides the personal aspect there is a huge social and economic impact. Alzheimer´s disease is recognized as a significant health crisis of the 21st century with currently more than
36 million patients worldwide. This number is expected to double in the next 20 years and to triple to more than 116 million by 2050. In 2010 global worldwide costs were estimated to be USD 604 billion and were exceeding 1% of the global domestic product (Reference: World Alzheimer Report 2011, Alzheimer’s Disease International).

Scientists don’t yet fully understand what causes Alzheimer’s disease, but it has become increasingly clear that it develops because of a complex series of events that take place in the brain over a long period of time. Two proteins – Tau and Abeta – are perceived as the major causes of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells, while plaques and oligomers formed by Abeta occur outside the brain cells of people with Alzheimer’s disease.

About AC Immune SA
AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s disease drug development. AC Immune develops innovative therapeutics with “best in class” potential against Alzheimer´s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody (crenezumab) for passive immunization is partnered with Genentech and is in Phase II development. The company continues to develop in house the small molecule ACI-91 and the vaccine ACI-24 in Phase II and Phase I/IIa clinical development respectively. These three clinical programs are focused on Alzheimer’s disease, and are backed by a rich portfolio of preclinical compounds. The therapeutic molecules are also leveraged for Alzheimer´s disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma. Since its foundation in 2003, AC Immune has raised CHF 64 million from private investors.

-Anita M. Harris
Disclosure: I will be working with AC Immune at the Biotechnology Industry Organization today in Boston.

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.

Tim Rowe, CEO of the Cambridge Innovation Center in Kendall Square, gave a great talk at HarrisCom Group’s recent Pitching for Business Workshop on Feb. 23.  Among his main points: “Elevator pitching is like dating:” the goal is to find out if it’s worth spending more time with the person you’re speaking to. Tim is also a venture capitalist and president of the Kendall Square Association in Cambridge, MA.

Here are links to the video and to the blog I wrote on the HarrisCom Web site.

Link to video
Link to blog  

–Anita M. Harris
Anita M. Harris is president of the Harris Communications Group of Cambridge, MA, an award-winining public relations 3.0 firm specializing in strategic integrated marketing communications and thought leadership  for clients in health, science, energy, technology and education, worldwide. 

My friend SG forwarded this email…thought I’d share it with my readers.  If you have suggestions, please add them in comments, below. If you originated it, please let me know and I’ll link to you. Thanks! Anita

Senior Discounts

(If you’re not a senior, please pass this on to someone who is!)

As I was waiting in line behind an older gentleman at Wendy’s recently, I heard him ask for his senior discount. The girl at the register apologized and charged him less. When I asked the man what the discount was, he told me that seniors over 55 get 10% off everything on the menu, every day.

Being that age myself, I figured I might as well ask for the discount too. As I waited for my turn, I thought about the consequences of doing so. If the employee asked me for I.D., it could be embarrassing having to show my license. But if she didn’t ask for proof, I would get depressed that I really did look “old” and that I didn’t need to prove it. Since I always like to save money, I boldly asked for the discount, and sadly she just rang up the discount (even though I am convinced I don’t look a day over 54).

Anyway, this incident prompted me to do some research, and I came across a list of restaurants, supermarkets, department stores, travel deals and other types of offers giving various discounts with different age requirements. I was actually surprised to see how many there are and how some of them start at the young age of 50.

This list may not only be useful for you, your friends and family, but it might also be appreciated by your clients. You might consider sending them an e-mail about it and link to our site in the e-mail, or maybe include it in your newsletter.

Dunkin Donuts gives free coffee to people over 55. If you’re paying for a cup every day, you might want to start getting it for free.

Restaurants

Applebee’s: 15% off with Golden Apple Card (60+)
Arby’s: 10% off (55+)
Ben & Jerry‘s: 10% off (60+)
Bennigan’s: discount varies by location
Bob’s Big Boy: discount varies by location (60+)
Boston Market: 10% off (65+)
Burger King: 10% off (60+)
Captain D’s Seafood: discount varies on location (62+)
Chick-Fil-A: 10% off or free small drink or coffee (55+)
Chili’s: 10% off (55+)
CiCi’s Pizza: 10% off (60+)
Culver’s: 10% off (60+)
Denny’s: 10% off, 20% off for AARP members (55+)
Dunkin’ Donuts: 10% off or free coffee (55+)
Einstein’s Bagels: 10% off baker�s dozen of bagels (60+)
Fuddrucker’s: 10% off any senior platter (55+)
Gatti’s Pizza: 10% off (60+)
Golden Corral: 10% off (60+)
Hardee’s: $0.33 beverages everyday (65+)
IHOP: 10% off (55+)
Jack in the Box: up to 20% off (55+)
KFC: free small drink with any meal (55+)
Krispy Kreme: 10% off (50+)
Long John Silver’s: various discounts at participating locations (55+)
McDonald’s: discounts on coffee everyday (55+)
Mrs. Fields: 10% off at participating locations (60+)
Shoney’s: 10% off
Sonic: 10% off or free beverage (60+)
Steak ‘n Shake: 10% off every Monday & Tuesday (50+)
Subway: 10% off (60+)
Sweet Tomatoes: 10% off (62+)
Taco Bell: 5% off; free beverages for seniors (65+)
TCBY: 10% off (55+)
Tea Room Cafe: 10% off (50+)
Village Inn: 10% off (60+)
Waffle House: 10% off every Monday (60+)
Wendy’s: 10% off (55+)
White Castle: 10% off (62+)

Retail And Apparel

Banana Republic: 10% off (50+)
Bealls: 20% off first Tuesday of each month (50+)
Belk’s: 15% off first Tuesday of every month (55+)
Big Lots: 10% off
Bon-Ton Department Stores: 15% off on senior discount days (55+)
C.J. Banks: 10% off every Wednesday (60+)
Clarks: 10% off (62+)
Dress Barn: 10% off (55+)
Goodwill: 10% off one day a week (date varies by location)
Hallmark: 10% off one day a week (date varies by location)
Kmart: 20% off (50+)
Koh‘�s: 15% off (60+)
Modell‘s Sporting Goods: 10% off
Rite Aid: 10% off on Tuesdays & 10% off prescriptions
Ross Stores: 10% off every Tuesday (55+)
The Salvation Army Thrift Stores: up to 50% off (55+)
Stein Mart:: 20% off red dot/clearance items first Monday of every month (55+)

Grocery

Albertson’s: 10% off first Wednesday of each month (55+)
American Discount Stores: 10% off every Monday (50+)
Compare Foods Supermarket: 10% off every Wednesday (60+)
DeCicco Family Markets: 5% off every Wednesday (60+)
Food Lion: 6% off every Monday (60+)
Fry’s Supermarket: free Fry�s VIP Club Membership & 10% off every Monday (55+)
Great Valu Food Store: 5% off every Tuesday (60+)
Gristedes Supermarket: 10% off every Tuesday (60+)
Harris Teeter: 5% off every Tuesday (60+)
Hy-Vee: 5% off one day a week (date varies by location)
Kroger: 10% off (date varies by location)
Morton Williams Supermarket: 5% off every Tuesday (60+)
The Plant Shed: 10% off every Tuesday (50+)
Publix: 5% off every Wednesday (55+)
Rogers Marketplace: 5% off every Thursday (60+)
Uncle Guiseppe’s Marketplace: 5% off (62+)

Travel

Alaska Airlines: 10% off (65+)
Alamo: up to 25% off for AARP members
American Airlines: various discounts for 65 and up (call before booking for discount)
Amtrak: 15% off (62+)
Avis: up to 25% off for AARP members
Best Western: 10% off (55+)
Budget Rental Cars: 10% off; up to 20% off for AARP members (50+)
Cambria Suites: 20%-30% off (60+)
Clarion: 20%-30% off (60+)
Comfort Inn: 20%-30% off (60+)
Comfort Suites: 20%-30% off (60+)
Continental Airlines: no initiation fee for Continental Presidents Club & special fares for select destinations
Dollar Rent-A-Car: 10% off (50+)
Econo Lodge: 20%-30% off (60+)
Enterprise Rent-A-Car: 5% off for AARP members
Greyhound: 5% off (62+)
Hampton Inns & Suites: 10% off when booked 72 hours in advance
Hertz: up to 25% off for AARP members
Holiday Inn: 10%-30% off depending on location (62+)
Hyatt Hotels: 25%-50% off (62+)
InterContinental Hotels Group: various discounts at all hotels (65+)
Mainstay Suites: 10% off with Mature Traveler�s Discount (50+); 20%-30% off (60+)
Marriott Hotels: 15% off (62+)
Motel 6: 10% off (60+)
Myrtle Beach Resort: 10% off (55+)
National Rent-A-Car: up to 30% off for AARP members
Quality Inn: 20%-30% off (60+)
Rodeway Inn: 20%-30% off (60+)
Sleep Inn: 20%-30% off (60+)
Southwest Airlines: various discounts for ages 65 and up (call before booking for discount)
Trailways Transportation System: various discounts for ages 50 and up
United Airlines: various discounts for ages 65 and up (call before booking for discount)
U.S. Airways: various discounts for ages 65 and up (call before booking for discount)

Activities And Entertainment

AMC Theaters: up to 30% off (55+)
Bally Total Fitness: up to $100 off memberships (62+)
Busch Gardens Tampa: $3 off one-day tickets (50+)
Carmike Cinemas: 35% off (65+)
Cinemark/Century Theaters: up to 35% off
U.S. National Parks: $10 lifetime pass; 50% off additional services including camping (62+)
Regal Cinemas: 30% off
Ripley�s Believe it or Not: @ off one-day ticket (55+)
SeaWorld Orlando: $3 off one-day tickets (50+)

Cell Phone Discounts

AT&T: Special Senior Nation 200 Plan $29.99/month (65+)
Jitterbug: $10/month cell phone service (50+)
Verizon Wireless: Verizon Nationwide 65 Plus Plan $29.99/month (65+).

Miscellaneous

Great Clips: $3 off hair cuts (60+)
Super Cuts: $2 off haircuts (60+)

I have already been told that A&P supermarkets offers 5% off to people over 55 every Tuesday. If you know of any other senior deals that aren’t on the list, please let me know.

*

[Again–this list came to my attention via email; happy to credit whoever compiled it]
Anita Harris

New Cambridge Observer is a publication of the award-winning  Harris Communications Group of Cambridge, MA,  specializing in PR 3.0 for clients in health, science, technology and energy, worldwide.

My friend Bill Lichtenstein is working on what’s certain to be a wonderful nonprofit documentary film about WBCN–a groundbreaking Boston radio station deeply involved in the political and cultural changes of the 1960s.  He’s seeking funding through Kickstarter: an innovative fundraising mechanism that will be of interest to entrepreneurs of all stripes–in order to help change the future.

The film, entitled  “The American Revolution: How a Radio Station, Politics and Rock and Roll Changed Everything”  documents Boston radio station WBCN from 1968 (when Bill, as a 14-year-old high school became the station’s youngest DJ) through 1974.

As reported in the Boston Herald (Dec. 5, 2011), during those years, Bruce Springsteen did his first radio interview ever on WBCN;  Jerry Garcia and Bob Weir,  of the Grateful Dead, and  the Allman Brothers’ Duane Allman stopped into the studio at 2 AM and jammed for an area. When Nixon invaded Cambodia, “BCN got local college kids to strike.

WBCN  “had tremendous national impact both musically and politically,” Lichtenstein told the Herald. “We changed the world one time,” Lichtenstein says.  And, with this film,  “we can do it again.”

Lichenstein, who has produced TV news and documentaries for ABC and PBS, has gathered more than 50,000 documents, photos,  and tapes–which include performances by Led Zeppelin, Lou Reed and the Velvet Underground.

He has also garnered some $50,000 in contributions–but needs to double that amount by Dec. 19 to complete the film.

He’s  seeking $104 thousand in donations via Kickstarter–a nonprofit that allows contributors tax deductions–but gives fundraisers just a month to get the entire bundle.That is, Kickstarter takes an all or nothing approach:  Lichtenstein must  bring in all $104K by Dec. 19–or he gets nothing.

After three weeks of fundraising, he’s  now almost at the halfway point, with just a week to go.

More info and the film trailer are available at  www.KickstartWBCN.com.  Lichtenstein and Kickstarter will be featured on Boston’s WCVB-TV  “Chronicle”  on Dec. 13, 2011.

——Anita Harris

Anita M. Harris is president of the Harris Communications Group, an award-winning public relations firm located in tyhe Cambridge Innovation Center in Kendall Square,  Cambridge, MA.   Anita  is a former national journalist who got HER start in the alternative press–as a founder of the Harrisburg Independent Press and writer for  the The Real Paper and Phoenix in Boston, MA.

Feb. 17, 2011
Perhaps I spoke too soon about that neighborliness in tough times thing.

The day after I posted the photo of the snowman on the bench in the Cambridge Common, someone  knocked the bow-tied guy down.

Ice is making it hard to walk, and, now, there’s a layer of dirt on huge mounds of -snow to the point where it’s difficult to see where you’re going.

My friend E and I almost got killed  driving on Route 2 when a car scooted out from behind a drift that must have blocked that  driver’s view.

Six weeks into this,  I’m rarely taking out my car: not only is it it risky to drive, but where on earth will I find a place to park when I get back?

In for the winter?

In my neighborhood, many people still have not dug out their cars;  I have, several times,  but even so, to avoid driving around all night,  I’ve been skipping meetings–or using public transportation when I can.

One of my neighbors decided to brave it–but when she went out to her car, she found it parked in so tightly that even the American Automobile Association couldn’t tow her out.  She left an angry note,  keyed the offending car, then called the police, who said they couldn’t do anything because both her car and the offender’s were illegally parked.

A student at Harvard Law who grew up in LA asked  how anyone can live here for a lifetime. “It’s so depressing!” he said. I told him that some years, we don’t get any snow at all–and that, even this year,  it could be worse: .  he  could be at Cornell Law, in Ithaca, NY or  SUNY Albany, or, worse yet,  Buffalo.  My  (I see now)  obnoxious advice to him? Learn to love skiing and–chill out. Spring will come.”

Feb. 21, 2011
That was then. This is now. Over the weekend, someone bashed in the driver’s side of my parked car…I’m guessing  $700 damage.  And–it’s snowing again!

I say…so much for neighborliness.  Like winter, evidently, it  only lasts so long!

Anita M. Harris

New Cambridge Observer is a publication of the  Harris Communications Group, a marketing communications and public relations firm in Cambridge, MA.